Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: Patient management considerations

BACKGROUND: Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsing-remitting multiple sclerosis (MS), is a disease-modifying therapy with potential immunomodulatory and neuroprotective effects. In clinical trials, DMF was associated with reduced white blood c...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Robert J., Chan, Andrew, Gold, Ralf, Phillips, J. Theodore, Selmaj, Krzysztof, Chang, Ih, Novas, Mark, Rana, Jitesh, Marantz, Jing L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909524/
https://www.ncbi.nlm.nih.gov/pubmed/27347439
http://dx.doi.org/10.1212/CPJ.0000000000000238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909524/
https://www.ncbi.nlm.nih.gov/pubmed/27347439
http://dx.doi.org/10.1212/CPJ.0000000000000238

Ejemplares similares